Sakar Healthcare · tone and specificity signals across the available quarters.
Language signals
We have already received five marketing authorizations from the EU region and one from entire Europe extra that is total six. Now considering that we are currently having submitted another 18-19 dossiers in across Europe. So these are about to come up and these will add up to the overall list of marketing authorizations within the next financial year.
We have developed full basket of 10-12 products which we have developed. So this is a unique feature which we presently hold and which our competitors are not having.
This is the only first of a series of oncology products expected to be commercialized through similar regulatory pathways. Our dossier progress has remained strong of 211 oncology dossiers submitted globally.
The benefits of these investments are now beginning to materialize.
We have already signed more than 60 oncology business contracts with over 35 discussions currently ongoing.
The accord intact portfolio alone comprising 10 oncology products to be manufactured by SAK represents a potential opportunity of rupees 50 cr to 100 cr.